Q32 Bio Inc.
Q32 Bio Inc. (QTTB): 3 pipeline candidates · 2 upcoming catalysts · ~25 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
25.1 months
D/E 0.37 · 0% dilution
Lead: Phase 2
3 candidates
2 upcoming, next in ~12d
4 buys · 3 sells (180d)
A transparent, data-derived signal for Q32 Bio Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$218.1M
Cash
$51.4M
Quarterly Burn
$6.3M
Runway
25.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| adx-096 | Phase 2 |
| adx-097 | Phase 2 |
| bempikibart | Phase 2 |
Upcoming Catalysts (2)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
49
Total value held
$31.2M
| Holder | Shares | Value |
|---|---|---|
| orbimed advisors llc | 2,252,987 | $14.5M |
| vanguard capital management llc | 612,802 | $3.9M |
| arch venture management, llc | 320,482 | $2.1M |
| acorn capital advisors, llc | 315,052 | $2.0M |
| mackenzie financial corp | 246,304 | $1.6M |
| renaissance technologies llc | 206,915 | $1.3M |
| monimus capital management, lp | 134,310 | $862K |
| geode capital management, llc | 118,152 | $759K |
| pfizer inc | 101,618 | $737K |
| blackrock, inc. | 86,147 | $553K |
Showing top 10 of 49 institutional holders of Q32 Bio Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Q32 Bio Inc.'s pipeline?
Q32 Bio Inc. (QTTB) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Q32 Bio Inc.'s lead drug candidate?
Q32 Bio Inc.'s most advanced tracked candidate is adx-096 (Phase 2) for Ophthalmologic indications.
What is Q32 Bio Inc.'s next catalyst?
Q32 Bio Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: bempikibart" — expected June 30, 2026.
What is Q32 Bio Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Q32 Bio Inc. has approximately 25.1 months of cash runway.
What is Q32 Bio Inc.'s market capitalization?
Q32 Bio Inc.'s market capitalization is approximately $218.1M.
Get the full picture on Q32 Bio Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.